Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) – Stock analysts at HC Wainwright issued their Q1 2024 earnings estimates for Prelude Therapeutics in a research note issued on Thursday, August 17th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.61) per share for the quarter. HC Wainwright currently has a “Buy” rating […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.